Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021
2021; European Centre for Disease Prevention and Control; Volume: 26; Issue: 39 Linguagem: Inglês
10.2807/1560-7917.es.2021.26.39.2100894
ISSN1560-7917
AutoresIván Martínez‐Baz, Camino Trobajo‐Sanmartín, Ana Miqueleiz, Marcela Guevara, Miguel Fernández-Huerta, Cristina Burgui, Itziar Casado, María Eugenia Portillo, Ana Navascués, Carmen Ezpeleta, Jesús Castilla,
Tópico(s)COVID-19 epidemiological studies
ResumoCOVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (-26 to 45) for Janssen to 68% (48 to 80) for Spikevax; and against hospitalisation from 74% (43 to 88) for Janssen to > 90% for other products. Two doses of vaccine were highly effective against hospitalisation, but suboptimal for infection control.
Referência(s)